pamidronate has been researched along with Cancer of Kidney in 8 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pamidronate is a second generation bisphosphonate used for treating tumor-induced hypercalcemia and for preventing the development of new bone metastasis." | 7.69 | [Effect of pamidronate and interferon-alpha on bone and lung metastases and hypercalcemia in a patient with renal cell carcinoma]. ( Arima, K; Hioki, T; Kawamura, J; Kise, H; Kobayashi, K; Sugiura, Y; Tochigi, H; Yanagawa, M, 1996) |
| "Pamidronate is a second generation bisphosphonate used for treating tumor-induced hypercalcemia and for preventing the development of new bone metastasis." | 3.69 | [Effect of pamidronate and interferon-alpha on bone and lung metastases and hypercalcemia in a patient with renal cell carcinoma]. ( Arima, K; Hioki, T; Kawamura, J; Kise, H; Kobayashi, K; Sugiura, Y; Tochigi, H; Yanagawa, M, 1996) |
| "Congenital mesoblastic nephroma is a rare pediatric renal tumor and has been reported in patients presenting with palpable abdominal mass, arterial hypertension, hematuria, polyuria, or hypercalcemia." | 1.72 | Severe neonatal hypercalcemia revealing congenital mesoblastic nephroma: A case report and management of neonatal hypercalcemia: Severe neonatal hypercalcemia revealing congenital mesoblastic nephroma. ( Bacchetta, J; Bordet, F; Dijoud, F; Duncan, A; Mure, PY; Pracros, JP; Tanné, C, 2022) |
| "Main indications for BP treatment were breast cancer (36%), multiple myeloma (24%), prostate cancer (16%) and kidney cancer (4%)." | 1.42 | Risk factors influencing the duration of treatment with bisphosphonates until occurrence of an osteonecrosis of the jaw in 963 cancer patients. ( Felsenberg, D; Gabbert, TI; Hoffmeister, B, 2015) |
| "We report a renal cell carcinoma case in which multiple lung and bone metastases displayed remarkable remission to BP therapy using 30 mg pamidronate once, 4 mg zoledronate once, and weekly 10 mg incadronate 10 times for 3 months." | 1.35 | Lung and bone metastases from renal cell carcinoma responsive to bisphosphonates: a case report. ( Fujii, Y; Fukui, I; Kijima, T; Okubo, Y; Suyama, T; Yonese, J, 2008) |
| "Zoledronic acid was consistently more potent than pamidronate for inducing apoptotic cell death." | 1.33 | Antitumor effects of aminobisphosphonates on renal cell carcinoma cell lines. ( Anderson, C; Birchall, L; Harrington, K; Meyer, B; Pandha, H; Relph, K; Wilson, N, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (25.00) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Tanné, C | 1 |
| Pracros, JP | 1 |
| Dijoud, F | 1 |
| Mure, PY | 1 |
| Bordet, F | 1 |
| Duncan, A | 1 |
| Bacchetta, J | 1 |
| McKay, RR | 1 |
| Lin, X | 1 |
| Perkins, JJ | 1 |
| Heng, DY | 1 |
| Simantov, R | 1 |
| Choueiri, TK | 1 |
| Gabbert, TI | 1 |
| Hoffmeister, B | 1 |
| Felsenberg, D | 1 |
| Pandha, H | 1 |
| Birchall, L | 1 |
| Meyer, B | 1 |
| Wilson, N | 1 |
| Relph, K | 1 |
| Anderson, C | 1 |
| Harrington, K | 1 |
| Kijima, T | 1 |
| Fujii, Y | 1 |
| Suyama, T | 1 |
| Okubo, Y | 1 |
| Yonese, J | 1 |
| Fukui, I | 1 |
| Kise, H | 1 |
| Kobayashi, K | 1 |
| Arima, K | 1 |
| Yanagawa, M | 1 |
| Tochigi, H | 1 |
| Kawamura, J | 1 |
| Hioki, T | 1 |
| Sugiura, Y | 1 |
| Akbulut, H | 1 |
| Icli, F | 1 |
| Morton, AR | 1 |
| Friefeld, J | 1 |
| Halperin, F | 1 |
8 other studies available for pamidronate and Cancer of Kidney
| Article | Year |
|---|---|
Severe neonatal hypercalcemia revealing congenital mesoblastic nephroma: A case report and management of neonatal hypercalcemia: Severe neonatal hypercalcemia revealing congenital mesoblastic nephroma.
Topics: Calcium; Female; Food, Fortified; Furosemide; Humans; Hypercalcemia; Hypertension; Infant Formula; I | 2022 |
Prognostic significance of bone metastases and bisphosphonate therapy in patients with renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Axitinib; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Dens | 2014 |
Risk factors influencing the duration of treatment with bisphosphonates until occurrence of an osteonecrosis of the jaw in 963 cancer patients.
Topics: Aged; Bone Density Conservation Agents; Breast Neoplasms; Diphosphonates; Disease-Free Survival; Fem | 2015 |
Antitumor effects of aminobisphosphonates on renal cell carcinoma cell lines.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Renal Cell; Cell Death; Cell Line, Tumor; Cell Prolifer | 2006 |
Lung and bone metastases from renal cell carcinoma responsive to bisphosphonates: a case report.
Topics: Bone Density Conservation Agents; Bone Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Humans; Imi | 2008 |
[Effect of pamidronate and interferon-alpha on bone and lung metastases and hypercalcemia in a patient with renal cell carcinoma].
Topics: Antineoplastic Agents; Bone Neoplasms; Carcinoma, Renal Cell; Diphosphonates; Humans; Hypercalcemia; | 1996 |
Overdosage of pamidronate in a patient with renal cell carcinoma.
Topics: Aged; Anti-Inflammatory Agents; Carcinoma, Renal Cell; Diphosphonates; Female; Humans; Hypercalcemia | 2000 |
Dose of bisphosphonate for hypercalcaemia of malignancy.
Topics: Aged; Carcinoma, Renal Cell; Diphosphonates; Female; Humans; Hypercalcemia; Infusions, Intravenous; | 1990 |